Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,116,678 ordinary shares of 25 pence each.
- Purchase Price: 1,485.19 pence per share.
- Treasury Holdings: Following the transaction, the company holds 142,779,678 shares in Treasury.
- Shares in Issue: 5,818,221,164 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 25, 2005. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the standard disclaimer that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total cost of the repurchase transaction (1,116,678 shares at 1,485.19 pence).
- Confirm the updated total number of shares in issue and Treasury holdings.
- Review the Annual General Meeting minutes from May 25, 2005, to confirm the scope of the share buyback authority.